Universal pennystocks.com focus is on Hot Penny Stocks that trade on OTCBB and OTC markets, which are mostly referred to as “penny stocks”. These Penny Stocks could offer the greatest potential return on your short or long term investment. Sign up for our free newsletter before you miss the next alert.
Scottsdale, AZ -- (SBWIRE) -- 01/28/2013 -- Amgen, Inc. (NASDAQ:AMGN) ended higher by 0.80 points or 0.97% to complete the day at 83.42. The total number of shares changed hands during the day was 7.24 million. After opening at $82.73, the stock hit as high as $83.43. However, it traded between $65.37 and$90.81over the last twelve months. Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada.
Will AMGN Continue To Move Higher? Find Out Here
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) closed yesterday at $8.71, a 0.46% increase. Around 5.35 million shares were traded, down from an-average trading volume of 11.48 million shares. The company is now valued at around $1.89 billion. Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases.
Why Should Investors Buy ARNA After The Recent Gain? Just Go Here and Find Out
Celgene Corporation (NASDAQ:CELG) moved 2.33per cent higher at $99.76 and traded between $96.30 and $99.90 after opening the day at $96.42. Its performance over the last five days remained 3.59%, which stands at 26.95% for a month. Going back further than one month, 1-year performance after recent close was 35.97%.Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases primarily in the United States and Europe.
What was the Moving Force behind CELG On Bullish Run? Read This Research Report on CELG
VIVUS, Inc. (NASDAQ:VVUS) shares decline, dropping -4.55 per cent to close at $12.39. The stock is down around -7.68% this year and 2.91% for the last 12 months. Around 4.98 million shares changed hands yesterday, lower from an-average trading volume of 5.44 million shares. VIVUS, Inc., a biopharmaceutical company, is developing therapies to address obesity, sleep apnea, diabetes, and male sexual health.
Will VVUS Get Buyers Even After The Recent Rally? Find Out Here
The share price of Gilead Sciences, Inc. (NASDAQ:GILD) after ranging between $78.37and $79.37 ended -49.39% lower to settle at $39.68.During the past 52 weeks, the stock has ranged from a high of $79.37 to a low of $43.81.So far this year, shares have gained 8.06% and 1-year performance was around 62.89%.Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases worldwide.
Has GILD Found The Bottom and Ready To Move Up? Find Out Here
About Universal Penny Stocks
Universalpennystocks.com is an Independent Company, our focus is on small cap stocks that trade on OTCBB and OTC markets, and are mostly referred to as “penny stocks”. These are stocks that normally trade under $5 a share and could offer the greatest potential return on your short or long term investment. You must read our Disclaimer page for more information regarding conflicts of interest and the risks involved.
We try to spot stocks in all types of market conditions. In addition, we provide emerging small cap companies with profiling and investor relations services for compensation. If you believe your company is an emerging company, with a solid product, or a company that offers our members a profitable short or long term opportunity please feel free to send us an e-mail and we’ll review the company and reply to your inquiry promptly. Please provide as much information you believe we’ll need to review your request.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)